Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of ABT-450/r/ABT-267 in Healthy Adults
NCT02052362Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of paritaprevir and ombitasvir in hepatitis C (HCV) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Absolute Bioavailability. Started Jan 2014; status: completed.
02
Drugs
paritaprevirombitasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02052362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052362.